• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Groenewald Ferdinand claimed ownership of 25,000 shares (SEC Form 3)

    1/15/25 4:58:47 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Groenewald Ferdinand

    (Last) (First) (Middle)
    C/O BIOSIG TECHNOLOGIES, INC.
    12424 WILSHIRE BLVD STE 745

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/13/2025
    3. Issuer Name and Ticker or Trading Symbol
    BioSig Technologies, Inc. [ BSGM ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, $0.001 par value per share 25,000(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares of stock were granted under the Company's 2023 Long-Term Incentive Plan.
    Remarks:
    Exhibit 24.1 Power of Attorney (furnished herewith)
    /s/ Anthony Amato attorney-in-fact 01/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BSGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on BioSig Technologies with a new price target

      The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

      2/8/21 7:32:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies' leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of

      5/28/25 6:45:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "combined company"), which today acquired Streamex Exchange Corporation ("Streamex") as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company. Mr. Willi

      5/28/25 1:46:57 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. Key Highlights of the Transaction: Streamex Exchange Corporation, a British Columbia corporation, will become a wholly owned subsidiary of BioSig through an exchange of outstanding shares of Streamex for new shares of BioSig common

      5/28/25 1:07:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BSGM
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      7/12/21 8:29:21 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Interim CFO Groenewald Ferdinand was granted 35,000 shares, increasing direct ownership by 140% to 60,000 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:56 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Amato Anthony N. was granted 23,345 shares, increasing direct ownership by 1% to 2,131,547 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:54 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Abelman Steven Eric was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:47 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

      Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

      9/22/22 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig to Host Conference Call on December 21, 2021

      Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

      12/13/21 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    SEC Filings

    See more
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/30/25 4:05:38 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/27/25 6:02:01 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by BioSig Technologies Inc.

      10-Q - BioSig Technologies, Inc. (0001530766) (Filer)

      5/19/25 1:19:49 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    See more
    • CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies' leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of

      5/28/25 6:45:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "combined company"), which today acquired Streamex Exchange Corporation ("Streamex") as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company. Mr. Willi

      5/28/25 1:46:57 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. Key Highlights of the Transaction: Streamex Exchange Corporation, a British Columbia corporation, will become a wholly owned subsidiary of BioSig through an exchange of outstanding shares of Streamex for new shares of BioSig common

      5/28/25 1:07:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care